{"product_id":"renovarobio-marketing-mix","title":"Renovaro Biosciences Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Renovaro Biosciences aligns product innovation, pricing strategy, distribution channels, and promotional tactics to build competitive advantage; this preview highlights key moves and gaps. Purchase the full 4Ps Marketing Mix Analysis for editable slides, data-driven insights, and actionable recommendations to apply immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell and gene therapy pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRenovaro develops advanced cell and gene therapies targeting oncology, HIV, and infectious diseases. Candidates span preclinical through clinical stages to de-risk across modalities. Platforms aim to harness and augment immune responses for durable efficacy. Roadmaps include biomarkers and companion diagnostics to guide patient selection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunotherapy platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eModular immunotherapy constructs are engineered to amplify tumor- and pathogen-specific immunity, with preclinical murine studies showing \u0026gt;70% tumor regression and anti-PD-1 combination improving survival ~40%. Differentiation emphasizes seamless combinability with standards of care and checkpoint inhibitors across 3 lead indications. Built-in safety switches and engineered specificity cut off-target activation by \u0026gt;90% in vitro. Data packages include GLP toxicology, translational immunology and mechanistic validation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage lead assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRenovaro's clinical-stage lead assets target indications with high unmet need using expedited pathways such as FDA Breakthrough Therapy, Fast Track, RMAT and Priority Review (six-month review clock). Trial designs emphasize binary primary endpoints, robust safety profiling and early efficacy signals to de-risk go\/no-go decisions. CMC and scalability plans are in place to enable seamless Phase 1\/2 to pivotal transitions and commercial manufacturing. Orphan and Breakthrough designations are pursued where eligible (US orphan: diseases affecting fewer than 200,000 people).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnabling diagnostics and biomarker strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompanion and complementary biomarker assays enable patient stratification and response monitoring, improving trial efficiency and raising response rates in enriched cohorts by as much as 20–30% in oncology studies; the global companion diagnostics market was ~USD 8.5B in 2023 with double-digit projected CAGR into 2028. Integrating real-world data strengthens health economic models and payer dossiers, while partnerships with diagnostic labs accelerate validation and commercial deployment.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStratification: enriches cohorts, +20–30% response\u003c\/li\u003e\n\u003cli\u003eMarket: ~USD 8.5B (2023), double-digit CAGR\u003c\/li\u003e\n\u003cli\u003eRWE: bolsters HEOR and reimbursement\u003c\/li\u003e\n\u003cli\u003ePartnerships: faster assay validation and rollout\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-centric design and delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRenovaro designs therapies for manageable administration—IV\/infusion or one-time gene delivery—with feasible monitoring and follow-up; as of 2024 the FDA has approved more than 20 cell and gene therapies, underscoring clinical and delivery precedents. Support services include adherence tools, AE management, and specialty pharmacy coordination; packaging meets cold-chain (2–8°C or frozen) and chain-of-identity requirements, with clinician and patient education materials to guide therapy steps.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdministration: IV\/infusion or one-time gene delivery\u003c\/li\u003e\n\u003cli\u003eSupport: adherence tools, AE management, specialty pharmacy\u003c\/li\u003e\n\u003cli\u003eLogistics: cold-chain (2–8°C or frozen), chain-of-identity\u003c\/li\u003e\n\u003cli\u003eEducation: clinician and patient stepwise materials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eModular cell\/gene: \u003cstrong\u003e\u0026gt;70%\u003c\/strong\u003e tumor regress; \u003cstrong\u003e\u0026gt;90%\u003c\/strong\u003e off-target\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRenovaro advances modular cell\/gene therapies across oncology, HIV and infectious disease with lead assets in clinical stages and GLP toxicology packages. Platforms enable \u0026gt;70% preclinical tumor regression and \u0026gt;90% in vitro off-target reduction; clinical strategy uses Breakthrough\/RMAT pathways and CMC scale plans. Companion diagnostics market ~USD 8.5B (2023); \u0026gt;20 FDA cell\/gene approvals by 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical tumor regression\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOff-target reduction in vitro\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompanion Dx market (2023)\u003c\/td\u003e\n\u003ctd\u003eUSD 8.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA CGT approvals (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Renovaro Biosciences’ Product, Price, Place, and Promotion strategies, grounded in real practices and competitive context for actionable insights. Ideal for managers, consultants, and marketers needing a structured, ready-to-use marketing positioning brief.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Renovaro Biosciences' 4P insights into a concise, leadership-ready snapshot that clarifies product, price, place, and promotion to resolve strategic ambiguity. Customizable and plug-and-play for decks, workshops, or cross-team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and comprehensive cancer centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInitial access via leading research hospitals and specialty clinics—including 72 NCI-designated cancer centers—targets key opinion leaders and concentrates Renovaro's early trials and launches. Concentrating trials at centers of excellence speeds prescriber adoption and leverages site networks to improve patient recruitment in a landscape where roughly 5% of adult cancer patients enroll in trials. Post-approval, these hubs anchor referral pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty distribution and cold-chain logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of 2025 Renovaro uses specialty pharmacies, 3PLs and dedicated cold-chain providers for biologics distribution; FDA requirements for chain-of-identity and chain-of-custody (autologous cell therapies) and EMA ATMP guidance are followed to ensure patient safety. Inventory is orchestrated just-in-time to cut cold-storage waste, and quality controls meet GMP across FDA, EMA and PMDA jurisdictions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCRO, CDMO, and hospital-based manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRenovaro leverages CROs to expand trial capacity and CDMOs to scale viral vector and cell therapy production, aligning with a CRO market exceeding USD 70B and a CDMO market above USD 30B (2023 industry reports).\u003c\/p\u003e\n\u003cp\u003eHospital-based cell processing supports point-of-care models in select indications, with over 100 US academic centers operating GMP cell facilities by 2024, enabling local manufacturing and faster patient delivery.\u003c\/p\u003e\n\u003cp\u003eA diverse partner network creates redundancy that mitigates supply risk and regional constraints, reducing single‑source exposure and supporting commercialization timelines into 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal market sequencing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLaunch prioritizes US and EU5 where reimbursement and expedited pathways accelerate uptake; FDA priority review goal is 6 months and EMA centralized assessment is 210 days. Subsequent entry targets Asia-Pacific via strategic partners; named-patient and early access programs bridge availability gaps while local regulatory and logistics adaptations ensure reliable supply.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket priority: US, EU5\u003c\/li\u003e\n\u003cli\u003eRegulatory timelines: FDA 6-month priority; EMA 210 days\u003c\/li\u003e\n\u003cli\u003eAPAC entry: strategic partners\u003c\/li\u003e\n\u003cli\u003eAccess: named-patient\/early access programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital clinician portals and patient navigation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpdigital clinician portals streamline ordering scheduling and adverse event reporting cutting administrative time supporting rapid site activation integrated educational modules onboard sites reduce operational friction with patient navigation teams coordinating travel labs follow-ups to lower no-show rates by up\u003e\u003cpdata integration enables outcomes tracking for payers and providers supporting value-based arrangements as roughly one-third of us health spend was tied to care by\u003e\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\u003cli\u003eSecure portals: faster ordering\/scheduling, AE reporting\u003c\/li\u003e\u003cli\u003eEducation: rapid site onboarding, ops friction reduction\u003c\/li\u003e\u003cli\u003eNavigation: travel, labs, follow-ups; no-shows down ~30%\u003c\/li\u003e\u003cli\u003eData: outcomes tracking for payers\/providers; ~33% value-based spend\u003c\/li\u003e\n\u003c\/pdata\u003e\u003c\/pdigital\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNCI hub network, cold‑chain delivery \u0026amp; CRO\/CDMO scale cut no‑shows ~30%, boost value care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePlace centers on 72 NCI centers and specialty clinics to speed adoption and patient recruitment where ~5% of adults join trials. Cold‑chain specialty pharmacies, 3PLs and hospital GMP sites (100+ US centers by 2024) enable just‑in‑time biologics delivery. CRO\/CDMO partnerships scale manufacturing (CRO \u0026gt;$70B; CDMO \u0026gt;$30B). Digital portals cut no‑shows ~30% and enable outcomes data for ~33% value‑based spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNCI centers\u003c\/td\u003e\n\u003ctd\u003e72\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial enrollment\u003c\/td\u003e\n\u003ctd\u003e~5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS GMP sites (2024)\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/CDMO markets (2023)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$70B \/ \u0026gt;$30B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNo‑shows reduction\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue‑based spend (US)\u003c\/td\u003e\n\u003ctd\u003e~33%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eRenovaro Biosciences 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual document you’ll receive instantly after purchase—no surprises. It contains Renovaro Biosciences’ complete 4P Marketing Mix analysis (Product, Price, Place, Promotion), fully editable and ready to use. You're viewing the exact version you'll download immediately after checkout. Buy with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55675225768313,"sku":"renovarobio-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/renovarobio-marketing-mix.png?v=1755804133","url":"https:\/\/portersfiveforce.com\/products\/renovarobio-marketing-mix","provider":"Porter's Five Forces","version":"1.0","type":"link"}